Liu S, Bugge T H, Leppla S H
Oral Infection and Immunity Branch and Oral and Pharyngeal Cancer Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Biol Chem. 2001 May 25;276(21):17976-84. doi: 10.1074/jbc.M011085200. Epub 2001 Mar 12.
Urokinase plasminogen activator receptor (uPAR) binds pro-urokinase plasminogen activator (pro-uPA) and thereby localizes it near plasminogen, causing the generation of active uPA and plasmin on the cell surface. uPAR and uPA are overexpressed in a variety of human tumors and tumor cell lines, and expression of uPAR and uPA is highly correlated to tumor invasion and metastasis. To exploit these characteristics in the design of tumor cell-selective cytotoxins, we constructed mutated anthrax toxin-protective antigen (PrAg) proteins in which the furin cleavage site is replaced by sequences cleaved specifically by uPA. These uPA-targeted PrAg proteins were activated selectively on the surface of uPAR-expressing tumor cells in the presence of pro-uPA and plasminogen. The activated PrAg proteins caused internalization of a recombinant cytotoxin, FP59, consisting of anthrax toxin lethal factor residues 1-254 fused to the ADP-ribosylation domain of Pseudomonas exotoxin A, thereby killing the uPAR-expressing tumor cells. The activation and cytotoxicity of these uPA-targeted PrAg proteins were strictly dependent on the integrity of the tumor cell surface-associated plasminogen activation system. We also constructed a mutated PrAg protein that selectively killed tissue plasminogen activator-expressing cells. These mutated PrAg proteins may be useful as new therapeutic agents for cancer treatment.
尿激酶型纤溶酶原激活物受体(uPAR)与纤溶酶原激活物原(pro - uPA)结合,从而将其定位在纤溶酶原附近,促使在细胞表面生成活性uPA和纤溶酶。uPAR和uPA在多种人类肿瘤及肿瘤细胞系中过表达,且uPAR和uPA的表达与肿瘤侵袭和转移高度相关。为在肿瘤细胞选择性细胞毒素设计中利用这些特性,我们构建了突变的炭疽毒素保护性抗原(PrAg)蛋白,其中弗林蛋白酶切割位点被uPA特异性切割的序列所取代。在pro - uPA和纤溶酶原存在的情况下,这些靶向uPA的PrAg蛋白在表达uPAR的肿瘤细胞表面被选择性激活。激活的PrAg蛋白导致重组细胞毒素FP59内化,FP59由与铜绿假单胞菌外毒素A的ADP - 核糖基化结构域融合的炭疽毒素致死因子1 - 254残基组成,从而杀死表达uPAR的肿瘤细胞。这些靶向uPA的PrAg蛋白的激活和细胞毒性严格依赖于肿瘤细胞表面相关纤溶酶原激活系统的完整性。我们还构建了一种选择性杀死表达组织纤溶酶原激活物细胞的突变PrAg蛋白。这些突变的PrAg蛋白可能作为癌症治疗的新型治疗药物有用。